Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 12, 2005, Pages 826-831

  Eliopoulos, G M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GLYCOPEPTIDE; LINCOSAMIDE; LINEZOLID; MACROLIDE; MIKAMYCIN B; MINOCYCLINE; NAFCILLIN; ORITAVANCIN; PENICILLIN DERIVATIVE; RIFAMPICIN; TELAVANCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIUM ISOLATE; BLOOD TOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; EMBOLISM; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; HUMAN; LACTIC ACIDOSIS; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUSCLE TOXICITY; MYALGIA; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TOXICITY; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 29944445801     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-0055-1     Document Type: Review

References (68)

1. Streit JM, Jones RN, Sader HS, Fritsche TR (2004) Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 24:111-118
2. Karlowsky JA, Jones ME, Draghi DC, Thornsberry C et al (2004) Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann Clin Microbiol Antimicrob 3:7
3. Witte W, Braulke C, Cuny C, Strommenger B et al (2005) Emergence of methicillin-resistant Staphylococcus aureus with Panton-Valentine leukocidin genes in central Europe. Eur J Clin Microbiol Infect Dis 24:1-5
4. Carleton HA, Diep BA, Charlebois ED, Sensabaugh GF, Perdreau-Remington F (2004) Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J Infect Dis 190:1730-1738
5. Howden BP, Ward PB, Charles PG, Korman TM et al (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38:521-528
6. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infec Dis 38:448-451
7. Fridkin SK, Hageman J, McDougal LK, Mohammed J et al (2003) Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 36:429-439
8. Noble WC, Virani Z, Cree RG (1992) Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 72:195-198
9. Centers for Disease Control and Prevention (2004) Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb Mortal Wkly Rep 53:322-333
10. Tenover FC, Weigel LM, Appelbaum PC, McDougal LK et al (2004) Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 48:275-280
11. Raad II, Hanna HA, Hachem RY, Dvorak T et al (2004) Clinical-use- associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob Agents Chemother 48:3583-3585
12. Zhanel GG, Laing NM, Nichol KA, Palatnick LP et al (2003) Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J Antimicrob Chemother 52:382-388
13. Sabol K, Patterson JE, Lewis JS, II, Owens A, Cadena J, Jorgensen JH (2005) Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 49:1664-1665
14. Herrero IA, Issa NC, Patel R (2002) Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Eng J Med 346:867-869
15. Baden LR, Thiemke W, Skolnik A, Chambers R et al (2001) Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term careJ patients and the significance of "clearance". Clin Infect Dis 33:1654-1660
16. Wong MT, Kauffman CA, Standiford HC, Linden P et al (2001) Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 33:1476-1482
17. Small PM, Chambers HF (1990) Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34:1227-1231
18. Levine DP, Fromm BS, Reddy BR (1991) Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115:674-680
19. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ (1999) Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 29:1171-1177
20. LaPlante KL, Rybak MJ (2004) Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48:4665-4672
21. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G et al (1996) Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 38:865-869
22. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ (1997) Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 17:990-997
23. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr (2004) Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38:1700-1705
24. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398-2402
25. Martinez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL (2003) Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 22:593-598
26. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH (2003) Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 41:4740-4744
27. Markowitz N, Quinn EL, Saravolatz LD (1992) Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 117:390-398
28. Iyer S, Jones DH (2004) Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 50:854-858
29. Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani R (1994) Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 38:1515-1518
30. Lawlor MT, Sullivan MC, Levitz RE, Quintiliani R, Nightingale C (1990) Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis 161:812-814
31. Eliopoulos GM (2003) Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 36:473-481
32. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481-1490
33. Weigelt J, Kaafarani HM, Itani KM, Swanson RN (2004) Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188:760-766
34. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH (2003) Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789-1797
35. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG (2004) Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30:388-394
36. Zimmer SM, Caliendo AM, Thigpen MC, Somani J (2003) Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis 37:e29-e30
37. Rao N, White GJ (2002) Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin Infect Dis 35:902-904
38. Babcock HM, Ritchie DJ, Christiansen E, Starlin R et al (2001) Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 32:1373-1375
39. Birmingham MC, Rayner CR, Meagher AK, Flavin SM et al (2003) Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36:159-168
40. Steinmetz MP, Vogelbaum MA, DeGeorgia MA, Andrefsky JC, Isada C (2001) Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med 29:2383-2385
41. Hachem R, Afif C, Gokaslan Z, Raad I (2001) Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 20:432-434
42. Zeana C, Kubin CJ, Della-Latta P, Hammer SM (2001) Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 33:477-482
43. Shaikh ZH, Peloquin CA, Ericsson CD (2001) Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 33:375-379
44. Meka VG, Gold HS (2004) Antimicrobial resistance to linezolid. Clin Infect Dis 39:1010-1015
45. Rho JP, Sia IG, Crum BA, Dekutoski MB, Trousdale RT (2004) Linezolid-associated peripheral neuropathy. Mayo Clin Proc 79:927-930
46. Lee E, Burger S, Shah J, Melton C, Mullen M et al (2003) Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 37:1389-1391
47. Palenzuela L, Hahn NM, Nelson RP Jr, Arno JN et al (2005) Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 40:e113-e116
48. Arbeit RD, Maid D, Tally FP, Campanaro E, Eisenstein BI (2004) The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38:1673-1681
49. Rezai K, Quinn JP, Hayes R, Lolans K et al (2004) Emergence of daptomycin (D) resistance and treatment failure in 2 cases of S. aureus osteomyelitis. Program and abstracts, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (2004) Abstract no. K-97a
50. Mangili A, Bica I, Snydman DR, Hamer DH (2005) Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40:1058-1060
51. Fritsche TR, Kirby JT, Jones RN (2004) In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 49:201-209
52. Dartois N, for the Tigecycline 305 CSSSI Study Group (2004) Results of a phase 3, double-blind, safety and efficacy study comparing tigecycline with vancomycin/aztreonam to treat complicated skin and skin-structure infections. Program and abstracts, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (2004) Abstract no. L-986
53. Nicas TI, Mullen DL, Flokowitsch JE, Preston DA et al (1996) Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother 40:2194-2199
54. Allen NE, Nicas TI (2003) Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 26:511-532
55. Wasilewski MM, Disch DP, McGill JM, Harris HW, et al (2001) Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin/skin structure infections. Program and abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (2001) Abstract no. UL-18
56. Loutit JS, O'Riordan W, San Juan J, Mensa J, et al (2004) Phase 2 trial comparing four regimens of oritavancin vs. comparator in the treatment of patients with S. aureus bacteremia. Program and abstracts, 14th European Congress on Clinical Microbiology & Infectious Disease, Prague, 2004, Abstract no. 541
57. Streit JM, Fritsche TR, Sader HS, Jones RN (2004) Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 48:137-143
58. Seltzer E, Dorr MB, Goldstein BP, Perry M et al (2003) Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 37:1298-1303
59. Debabov DV, Higgins DL, Chang R, Leung T et al (2004) The role of membrane permeabilization in the mode of action of telavancin against vancomycin-sensitive and -resistant enterococci. Program and abstracts, 44th Interscience Conference on Antimicrob Agents and Chemotherapy (2004) Abstract no. C1-952
60. Higgins DL, Chang R, Debabov V, Leung J et al (2004) Telavancin bactericidal activity against Staphylococcus aureus is mediated by multiple mechanisms. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (2004) Abstract no. C1-953
61. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD et al (2005) Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 40:1601-1607
62. Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P et al (2001) In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 45:825-836
63. Fung-Tomc JC, Clark J, Minassian B, Pucci M et al (2002) In vitro and in vivo activities of a novel cepohalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci. Antimicrob Agents Chemother 46:971-976
64. Chamberland S, Blais J, Hoang M, Dinh C et al (2001) In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria. Antimicrob Agents Chemother 45:1422-1430
65. Fujimura T, Yamano Y, Yoshida I, Shimada J, Kuwahara S (2003) In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci. Antimicrob Agents Chemother 47:923-931
66. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ (2002) In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 50:915-932
67. Schmitt-Hoffmann A, Nyman L, Roos B, Schleimer M et al (2004) Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 48:2576-2580
68. Chambers HF (2005) Evaluation of cebtobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 49:884-888